Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04094064 |
Recruitment Status :
Completed
First Posted : September 18, 2019
Results First Posted : December 21, 2022
Last Update Posted : December 21, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 | Device: Continuous Glucose Monitor | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD). |
Actual Study Start Date : | February 19, 2020 |
Actual Primary Completion Date : | September 29, 2021 |
Actual Study Completion Date : | September 29, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: CGM Use while on Hemodialysis Therapy
All subjects will use a CGM for 10 days. Subjects will continue their standard of care hemodialysis treatments during the study period.
|
Device: Continuous Glucose Monitor
Use of a continuous glucose monitor during study period. |
- Mean Absolute Relative Difference Between CGM Value and Capillary Blood Glucose (Self-monitoring Blood Glucose [SMBG]) [ Time Frame: From CGM placement to CGM removal (10 days) ]Mean Absolute Relative Difference (MARD) between CGM value and capillary blood glucose (SMBG) performed at home 4 to 7 times per day by the participant for 684 matched pairs.
- Mean Absolute Relative Difference (MARD) Between Continuous Glucose Monitor (CGM) Value and Venous Blood Glucose (vBGM) [ Time Frame: From CGM placement to CGM removal (10 days) ]Venous blood glucose samples were collected approximately 12 blood samples from the existing hemodialysis (HD) intravenous (IV) line during each (three) HD session the CGM sensor was worn. These blood samples were immediately processed using the i-STAT System. While the goal was to have the subject participate in three hemodialysis sessions, two sessions were acceptable. 624 matched data pairs were analyzed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ages 18+
- Type 1 diabetes mellitus on intermittent HD thrice weekly OR Type 2 diabetes mellitus on intermittent HD thrice weekly
- Willingness and ability to comply with scheduled visits and study procedures
Exclusion Criteria:
- Inability to comply with finger stick blood glucoses at least four times daily
- Noncompliant with HD therapies
- Pregnant women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04094064
United States, Virginia | |
Meaghan Stumpf, MD | |
Charlottesville, Virginia, United States, 22903 |
Principal Investigator: | Meaghan Stumpf, MD | University of Virginia |
Documents provided by Meaghan Stumpf, MD, University of Virginia:
Responsible Party: | Meaghan Stumpf, MD, Assistant Professor, University of Virginia |
ClinicalTrials.gov Identifier: | NCT04094064 |
Other Study ID Numbers: |
190012 |
First Posted: | September 18, 2019 Key Record Dates |
Results First Posted: | December 21, 2022 |
Last Update Posted: | December 21, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There are no current plans to share IPD for this study. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Dialysis Hemodialysis Diabetes Continuous Glucose Monitor (CGM) |
Kidney Failure, Chronic Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Kidney Diseases Urologic Diseases Female Urogenital Diseases |
Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Renal Insufficiency, Chronic Renal Insufficiency Chronic Disease Disease Attributes Pathologic Processes Autoimmune Diseases Immune System Diseases |